TY - JOUR
T1 - Updates on radiotherapy-immunotherapy combinations
T2 - Proceedings of 6th annual ImmunoRad conference
AU - Gregucci, Fabiana
AU - Spada, Sheila
AU - Barcellos-Hoff, Mary Helen
AU - Bhardwaj, Nina
AU - Chan Wah Hak, Charleen
AU - Fiorentino, Alba
AU - Guha, Chandan
AU - Guzman, Monica L.
AU - Harrington, Kevin
AU - Herrera, Fernanda G.
AU - Honeychurch, Jamie
AU - Hong, Theodore
AU - Iturri, Lorea
AU - Jaffee, Elisabeth
AU - Karam, Sana D.
AU - Knott, Simon R.V.
AU - Koumenis, Constantinos
AU - Lyden, David
AU - Marciscano, Ariel E.
AU - Melcher, Alan
AU - Mondini, Michele
AU - Mondino, Anna
AU - Morris, Zachary S.
AU - Pitroda, Sean
AU - Quezada, Sergio A.
AU - Santambrogio, Laura
AU - Shiao, Stephen
AU - Stagg, John
AU - Telarovic, Irma
AU - Timmerman, Robert
AU - Vozenin, Marie Catherine
AU - Weichselbaum, Ralph
AU - Welsh, James
AU - Wilkins, Anna
AU - Xu, Chris
AU - Zappasodi, Roberta
AU - Zou, Weiping
AU - Bobard, Alexandre
AU - Demaria, Sandra
AU - Galluzzi, Lorenzo
AU - Deutsch, Eric
AU - Formenti, Silvia C.
N1 - © 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.
PY - 2023
Y1 - 2023
N2 - Focal radiation therapy (RT) has attracted considerable attention as a combinatorial partner for immunotherapy (IT), largely reflecting a well-defined, predictable safety profile and at least some potential for immunostimulation. However, only a few RT-IT combinations have been tested successfully in patients with cancer, highlighting the urgent need for an improved understanding of the interaction between RT and IT in both preclinical and clinical scenarios. Every year since 2016, ImmunoRad gathers experts working at the interface between RT and IT to provide a forum for education and discussion, with the ultimate goal of fostering progress in the field at both preclinical and clinical levels. Here, we summarize the key concepts and findings presented at the Sixth Annual ImmunoRad conference.
AB - Focal radiation therapy (RT) has attracted considerable attention as a combinatorial partner for immunotherapy (IT), largely reflecting a well-defined, predictable safety profile and at least some potential for immunostimulation. However, only a few RT-IT combinations have been tested successfully in patients with cancer, highlighting the urgent need for an improved understanding of the interaction between RT and IT in both preclinical and clinical scenarios. Every year since 2016, ImmunoRad gathers experts working at the interface between RT and IT to provide a forum for education and discussion, with the ultimate goal of fostering progress in the field at both preclinical and clinical levels. Here, we summarize the key concepts and findings presented at the Sixth Annual ImmunoRad conference.
KW - dose and fractionation
KW - FLASH radiotherapy
KW - immune checkpoint inhibitors
KW - immunomodulators
KW - lymph node sparing
KW - tumor-associated macrophages
KW - Neoplasms/radiotherapy
KW - Humans
KW - Immunotherapy
KW - Combined Modality Therapy
UR - http://www.scopus.com/inward/record.url?scp=85162911591&partnerID=8YFLogxK
U2 - 10.1080/2162402X.2023.2222560
DO - 10.1080/2162402X.2023.2222560
M3 - Review article
C2 - 37363104
AN - SCOPUS:85162911591
SN - 2162-4011
VL - 12
JO - Oncoimmunology
JF - Oncoimmunology
IS - 1
M1 - 2222560
ER -